Prostate Cancer Working Group 3 (PCWG3) is an international working group of experts in prostate cancer who provided a framework for the assessment of subjects with castration-resistant prostate cancer enrolled in clinical trials. PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. We explore imaging assessment under PCWG3 in our new infographic.

Download our infographic to learn:

• The components of imaging evaluated under PCWG3
• The key points of assessment for these components
• Standards for determining progression

Complete the form to download your copy.